Skip to main content
Premium Trial:

Request an Annual Quote

Expression Analysis Claims GLP Compliance for Affy Services

NEW YORK, May 25 (GenomeWeb News) - Microarray service provider Expression Analysis said today that it has met all requirements for compliance with the Food and Drug Administration's good laboratory practice regulations.


The company said it took two years to develop and implement standard operating procedures, equipment and process validations, training, internal audits, and document control measures to meet the FDA's 21 CFR Part 58 guidelines for nonclinical laboratory studies.


According to Expression Analysis, it is now "the first company capable of providing Affymetrix GeneChip processes performed in compliance with GLP regulations."


Expression Analysis has already collaborated with the FDA as part of the agency's effort to standardize microarray data used in regulatory submissions. Steve McPhail, Expression Analysis' CEO, said in a statement that GLP compliance was "a logical next step" for the Durham, NC-based firm.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.